Medications for Anaplastic Lymphoma Kinase Fusion Oncogene Positive Nonsmall Cell Lung Cancer

2 results

  • alecensa

    (ALECTINIB HYDROCHLORIDE)
    Genentech, Inc.
    ALECENSA is indicated for adjuvant treatment in adults with resected ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adult patients with metastatic ALK-positive NSCLC, both detected by an FDA-approved test.

  • alunbrig

    (brigatinib)
    Takeda Pharmaceuticals America, Inc.
    ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) confirmed by an FDA-approved test.